Carmat SA
PAR:ALCAR

Watchlist Manager
Carmat SA Logo
Carmat SA
PAR:ALCAR
Watchlist
Price: 0.099 EUR Market Closed
Market Cap: €6.4m

Carmat SA
Investor Relations

Carmat SA engages in the developing of implantable orthotropic and biocompatible artificial heart. The company is headquartered in Velizy-Villacoublay, Ile-De-France and currently employs 160 full-time employees. The company went IPO on 2010-07-07. The firm is developing an orthotopic and biocompatible artificial heart which works like a natural heart and which is hydraulically activated. The firm formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels and Blood Institute, Laboratoire de Recherche Biochirurgicale and others. As of December 31, 2011, a company MATRA DEFENSE held a 30.57% stake in the Company’s shareholdings.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Mr. Stephane Piat
CEO & Director
No Bio Available
Ms. Pascale d'Arbonneau
CFO & Head of investor relations
No Bio Available
Ms. Raouia Bouyanzer
Human Resources Director
No Bio Available
Dr. Petrus Jansen
Chief Medical Officer
No Bio Available

Contacts

Address
ILE-DE-FRANCE
Velizy-Villacoublay
36, avenue de l'Europe, Immeuble l'Etendard
Contacts
+33139456450.0
www.carmatsa.com
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett